Hui Guo

Hui Guo

Auto-generated profile, based on publicly available information

Hui Guo

Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry , Chinese Academy of Sciences , Changchun , China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2018 in Advanced Science
Verified
Journal Article
Open access
PDF file
HGHui Guo
Hui Guo
FLFaping Li
Faping Li
WXWeiguo Xu
Weiguo Xu
JCJinjin Chen
Jinjin Chen
YHYuchuan Hou
Yuchuan Hou
Xuesi ChenXuesi Chen
Xuesi Chen
Initially, chemotherapy is effective for treatment of bladder cancer after transurethral resection of the bladder. However, certain patients progressively become unresponsive after multiple treatment cycles, which results from the rapid and almost complete excretion of clinically used formulations of antineoplastic agents with urinary voiding. Improving the mucoadhesiveness and penetrability of chemotherapeutic drugs are key factors in treatment of advanced bladder cancer. Here, a smart disulfide‐crosslinked polypeptide nanogel of poly(l‐lysine)–poly(l‐phenylalanine‐co‐l‐cystine) (PLL–P(LP‐co‐LC)) is developed to deliver 10‐hydroxycamptothecin (HCPT) for treatment of orthotopic bladder cancer. The positively charged PLL–P(LP‐co‐LC) can significantly prolong the retention period and enhance the tissue permeability of HCPT within the bladder wall of rat. Moreover, the reduction‐responsive polypeptide nanogel (i.e., NG/HCPT) possesses the capability to accurately and rapidly deliver HCPT in bladder cancer cells. NG/HCPT can significantly inhibit proliferation of human bladder cancer 5637 cells in vitro and enhance antitumor activity toward an orthotopic rat bladder cancer model in vivo. This work demonstrates that the smart polypeptide nanogel may function as a promising drug‐delivery system for local chemotherapy of bladder cancer with unprecedented clinical benefits.

1 August 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
HGHui Guo
Hui Guo
XWXu Weiguo
Xu Weiguo
JCJinjin Chen
Jinjin Chen
Lesan YanLesan Yan
Lesan Yan
Jianxun DingJianxun Ding
Jianxun Ding
Xuesi ChenXuesi Chen
Xuesi Chen

1 June 2020 in Trends in Biotechnology
Verified
Journal Article
Closed access
HQHeping Qiu
Heping Qiu
HGHui Guo
Hui Guo
DLDi Li
Di Li
YHYuchuan Hou
Yuchuan Hou
TKTairong Kuang
Tairong Kuang
Jianxun DingJianxun Ding
Jianxun Ding

4 April 2019 in International Journal of Polymer Science
Verified
Journal Article
Open access
PDF file
HGHui Guo
Hui Guo
FLFaping Li
Faping Li
HQHeping Qiu
Heping Qiu
QZQi Zheng
Qi Zheng
CYChao Yang
Chao Yang
YHYuchuan Hou
Yuchuan Hou
Chitosan (CS), the second most abundant polysaccharide in nature, has been widely developed as a nanoscopic drug delivery vehicle due to its intriguing characteristics. In this work, a positively charged CS-based nanogel was designed and synthesized to inhibit the proliferation of breast cancer cell lines. The model drug of 10-hydroxycamptothecin (HCPT) was entrapped into the core via a facile diffusion to form CS/HCPT. The characteristics of CS/HCPT were evaluated by assessing particle size, drug loading content, and drug loading efficiency. Furthermore, cell internalization, cytotoxicity, and apoptosis of CS/HCPT were also investigated in vitro. The present investigation indicated that the positively charged CS-based nanogel could be potentially used as a promising drug delivery system.

1 December 2018 in Medicine
Verified
Journal Article
Open access
LGLichao Gao
Lichao Gao
YJYanfang Jiang
Yanfang Jiang
YWYichen Wang
Yichen Wang
XQXiaozhang Qu
Xiaozhang Qu
LLLei Li
Lei Li
YLYa Liu
Ya Liu
Aberrant activation of the immune system has been reported in asymptomatic hyperuricemia (HUA) patients. However, very few studies have elucidated the role of natural killer (NK) cells in this disease. In this study, we evaluated the relationship between NK cells and HUA in 16 control subjects and 20 patients, who were all on a low-purine diet. We analyzed the number of circulating NK cells, its subsets, interferon-γ+, and CD107+ NK cells, by flow cytometry, before and after 4 and 24 weeks of diet control. We also assessed the potential association of the NK cells with clinical measures. The patients consistently had a lower number of NKG2D+ NK cells before and after low-purine diet, even the serum uric acid (SUA) levels <7 mg/dL after diet control. Moreover, a lower number of NK cells and a higher number of CD107a+ NK cells were observed on recruitment. Low-purine diet was benefit on the improvement of the SUA levels, body mass index (BMI), and the number and functions of NK cells. Furthermore, the number of CD3−CD56+ NK cells and NKG2D+ NK cells negatively correlated with the BMI before and after diet control. The consistent lower number of NKG2D+ NK cells and correlated with BMI before and after low-purine diet may be involved in the occurrence and development of HUA.

18 March 2024 in Oncologie
Verified
Journal Article
Open access
PDF file
HGHui Guo
Hui Guo
YHYuchuan Hou
Yuchuan Hou
CWChunxi Wang
Chunxi Wang
Jianxun DingJianxun Ding
Jianxun Ding
The realm of cancer therapy has been profoundly altered with the emergence of immune checkpoint blockade (ICB) therapy, providing improved survival prospects for many patients with some cancers. However, the challenge of achieving efficient or sustained therapeutic benefits underscores the critical imperative to optimize ICB strategies. This review elucidates the pivotal role of predictive biomarkers in optimizing precision ICB therapy, deciphering the intricate dynamics associated with the response heterogeneity. Furthermore, it critically examines the application of nanotechnology-driven drug delivery as a promising avenue to amplify ICB efficacy, facilitating controlled and targeted drug release. Recognizing the comprehensive and dynamic interplay among tumor cells, immune cells, and stromal cells has catalyzed the transformative advances in reverse translational research. This approach enables researchers to gain insights into the underlying mechanisms of ICB therapy, therapeutic responses, and resistance mechanisms. The convergence of predictive biomarkers, revolutionary nanotechnology, and reverse translational research emerges as an indispensable focal point, propelling the frontiers of precision oncology within the complex landscape of ICB therapy.